Freud AG, Zhao S, Wei S, Gitana GM, Molina-Kirsch HF, Atwater SK, Natkunam Y. Expression of the activating receptor, NKp46 (CD335), in human natural killer and T-cell neoplasia.
Am J Clin Pathol 2013;
140:853-66. [PMID:
24225754 DOI:
10.1309/ajcpwgg69mczowmm]
[Citation(s) in RCA: 31] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
OBJECTIVES
To evaluate the expression of CD335 (NKp46), an activation receptor that is selectively expressed on natural killer (NK) cells.
METHODS
We assessed CD335's potential utility as a diagnostic marker in 657 cases by flow cytometry and 410 cases by immunohistochemistry.
RESULTS
We observed that CD335 was highly specific for NK cells in nonneoplastic tissues. Moreover, 61 (90%) of 68 of NK cell neoplasms demonstrated CD335 expression, whereas B-cell, myelomonocytic, and plasma cell neoplasms lacked expression. Notably, 16 (20%) of 82 mature T-cell neoplasms, particularly T-cell large granular lymphocytic leukemia, mycosis fungoides, and ALK+ anaplastic large cell lymphoma, aberrantly expressed CD335.
CONCLUSIONS
Collectively, these data support the diagnostic utility of CD335 in evaluating hematopoietic malignancies and suggest that CD335 could be a useful target for selective immunotherapy in patients with mature NK and T-cell neoplasms.
Collapse